… autoimmune disease. FDA-approved therapies such as eculizumab (Soliris; Alexion), … experienced difficulties initiating treatment with novel NMOSD … inclusivity in clinical trials to better represent … even if your doctor prescribes these medications, sometimes it …

… global leader in the pharmaceutical, medical device and consumer … trials for new formulations of its blockbuster GLP-1 treatment … type 2 diabetes and Soliris for paroxysmal nocturnal … s largest biotechnology companies. Its leading commercial drugs include …

… vs the reference drug. The trial met its primary … and EAGLE-3 (NCT04187144) trials, which compared the efficacy and … Type 2 FDA Approves Expanded Indication of Eculizumab for Pediatric … ) approved by US FDA for treatment of uncomplicated urinary tract …

… alleged patent misuse in court. Soliris (eculizumab) was first approved for … buyout in 2020. The drug has since collected additional nods … optica spectrum disorder. The drug now competes with other PNH … Soliris was, for a time, one of the most expensive drugs …

… Soliris), in the US in April 2025. Eculizumab-aagh was approved by FDA … further expanding our biosimilars medicine portfolio and efforts to … now have an additional treatment option available at … , 2025. 2. Teva Pharmaceutical Industries. Teva and Samsung …

… Drug costs were derived from the Jiangsu Pharmaceutical Medical Consumables … patients, medical insurance and enterprises. Taking eculizumab as … treatment based on data from the ASTRUM-004 trial … evaluations alongside clinical trials--extrapolation with patient …

… covers all of the FDA-approved indications for Soliris (eculizumab), except for neuromyelitis … deemed interchangeable with the reference drug, meaning that pharmacists in the … factors including the high treatment cost." Soliris contributed $2.58 billion …

… an alkylating drug indicated in … treatment of motor fluctuations in adults with advanced Parkinson disease  Soliris (eculizumab … multicenter clinical trials. The trials assessed the … treatment-resistant depression, or in conjunction with an oral antidepressant …

… news outlet specializing in pharmaceutical industry analysis and data, … list of globally recognized medications set to lose their … in the treatment of leukemia, is another Novartis drug losing exclusivity … Europe due to biosimilars, Soliris earned $1.52 billion …

… of EPYSQLI® (eculizumab-aagh), a biosimilar referencing Alexion Pharmaceuticals’ SOLIRIS®.  As we reported … .S. Food and Drug Administration (FDA) for the treatment of three rare complement …